These studies demonstrate that the STAT1/STAT3 ratio may represent a useful biomarker to not only predict the degree of breast cancer immune suppression but also the type of immunotherapy that is most likely to yield durable clinical responses in individual breast tumours (Fig. 7). Here, STAT1 is linked to breast neoplasm.